Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Margaret A. Tempero

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2777-9208; OpenAlex author ID A5072641295; NIH RePORTER profile ID 1968873. Sources: ClinicalTrials.gov.

Their work

Papers
52 (first author 5, last author 3)
Trials
3 (principal investigator on 1)
Grants
1
Labs led
1
Collaborators
222
Papers, trials and grants by year

1998: 1 trial · 1999: none · 2000: none · 2001: 1 trial · 2002: none · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 3 papers · 2012: 3 papers · 2013: 3 papers · 2014: 3 papers · 2015: 2 papers, 1 trial, 1 grant · 2016: 5 papers · 2017: 7 papers · 2018: 2 papers · 2019: 6 papers · 2020: 6 papers · 2021: 5 papers · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 50 of 52

  1. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  2. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Co-author DOI 10.1200/po-25-00696↗
  3. Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-15579-0↗
  4. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
  5. Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jitc-2022-005425↗
  6. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  7. The Additional Diagnostic Benefit of Pancreatic Cancer Molecular Profiling After Germline Testing. Co-author DOI 10.1097/mpa.0000000000002021↗
  8. Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1002/onco.13968↗
  9. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE … Co-author DOI 10.1016/j.annonc.2021.01.070↗
  10. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Co-author DOI 10.1158/2159-8290.cd-20-0841↗
  11. Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with… Co-author DOI 10.1245/s10434-021-09816-z↗
  12. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2021.0017↗
  13. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.1016/j.ymthe.2020.07.017↗
  14. Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literat… Co-author DOI 10.1097/mpa.0000000000001507↗
  15. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-3978↗
  16. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. Co-author DOI 10.1172/jci136760↗
  17. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcin… First author DOI 10.1200/jco.20.00590↗
  18. Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2214/ajr.19.22462↗
  19. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Co-author DOI 10.1007/s10689-018-0106-2↗
  20. CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma. Last author DOI 10.1097/coc.0000000000000620↗
  21. Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000001354↗
  22. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stra… Co-author DOI 10.1097/pas.0000000000001152↗
  23. Pancreatic Adenocarcinoma, Version 1.2019. Co-author DOI 10.6004/jnccn.2019.0014↗
  24. NCCN Guidelines Updates: Pancreatic Cancer. Co-author DOI 10.6004/jnccn.2019.5007↗
  25. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. Co-author DOI 10.2214/ajr.18.19602↗
  26. HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. First author DOI 10.2217/fon-2017-0338↗
  27. Hypermutation In Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.09.060↗
  28. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. Co-author DOI 10.1093/jnci/djw266↗
  29. Introduction: Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies. Co-author DOI 10.1097/ppo.0000000000000295↗
  30. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAI… Co-author DOI 10.1634/theoncologist.2017-0066↗
  31. Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenoca… Co-author DOI 10.18632/oncotarget.22080↗
  32. Active Systemic Treatment of Pancreatic Cancer. Co-author DOI 10.6004/jnccn.2017.0084↗
  33. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2017.0131↗
  34. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? Co-author DOI 10.1002/jso.24375↗
  35. Pancreatic cancer. Co-author DOI 10.1038/nrdp.2016.22↗
  36. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000458↗
  37. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-15-0979↗
  38. Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies. Co-author DOI 10.1200/jop.2015.009753↗
  39. Whole genomes redefine the mutational landscape of pancreatic cancer. Co-author DOI 10.1038/nature14169↗
  40. Multidisciplinary management of pancreatic cancer. Co-author DOI 10.6004/jnccn.2015.0208↗
  41. HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. Co-author DOI 10.1002/nbm.3198↗
  42. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-con… Co-author DOI 10.1097/mpa.0000000000000095↗
  43. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. Co-author DOI 10.6004/jnccn.2014.0106↗
  44. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. First author DOI 10.1038/bjc.2013.408↗
  45. Therapeutic advances in pancreatic cancer. Co-author DOI 10.1053/j.gastro.2013.01.078↗
  46. Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-12-2745↗
  47. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Last author DOI 10.1007/s00280-012-1979-7↗
  48. Monoclonal antibodies and other targeted therapies for pancreatic cancer. First author DOI 10.1097/ppo.0b013e3182758985↗
  49. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. Co-author DOI 10.6004/jnccn.2012.0073↗
  50. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Co-author DOI 10.1038/nm.2344↗

Trials 3

  1. Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Principal investigator NCT02562898↗
  2. Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer Study chair NCT00025532↗
  3. Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer Study chair NCT00003546↗

Grants 1

  1. Perioperative Stromal Depletion Strategies in Pancreatic Ductal Adenocarcinoma R21CA184429↗

Closest collaborators

The 25 strongest of 222 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew H. Ko · 24 shared papers, 2011–2024 · strength 1.87
  2. Eric Andrew Collisson · 8 shared papers, 2011–2021 · strength 0.65
  3. Eric K. Nakakura · 8 shared papers, 2012–2024 · strength 0.57
  4. Pelin Cinar · 5 shared papers, 2012–2022 · strength 0.57
  5. Evan Justin Walker · 4 shared papers, 2016–2022 · strength 0.45
  6. Zhen J. Wang · 5 shared papers, 2016–2020 · strength 0.44
  7. Andrew Eugene Hendifar · 4 shared papers, 2020–2021 · strength 0.40
  8. Do‐Youn Oh · 4 shared papers, 2020–2021 · strength 0.40
  9. Teresa Mercade Macarulla · 4 shared papers, 2020–2021 · strength 0.40
  10. Lisa M. Coussens · 4 shared papers, 2020–2023 · strength 0.40
  11. Julia C. Carnevale · 3 shared papers, 2019–2022 · strength 0.40
  12. Grace Kim · 4 shared papers, 2011–2024 · strength 0.35
  13. Brian Matthew Wolpin · 6 shared papers, 2012–2021 · strength 0.33
  14. Sunhee S. Kim · 3 shared papers, 2016–2024 · strength 0.33
  15. Kimberly Saunders Kirkwood · 3 shared papers, 2016–2024 · strength 0.33
  16. Michele Reni · 3 shared papers, 2020–2021 · strength 0.32
  17. Lawrence H. Fong · 3 shared papers, 2020–2023 · strength 0.32
  18. Andrew M. Lowy · 6 shared papers, 2013–2021 · strength 0.31
  19. Chung‐Pin Li · 3 shared papers, 2020–2021 · strength 0.30
  20. Robert A. Wolff · 6 shared papers, 2012–2021 · strength 0.28
  21. Noelle K. LoConte · 4 shared papers, 2016–2021 · strength 0.25
  22. William G. Hawkins · 5 shared papers, 2012–2021 · strength 0.24
  23. Brian G. Czito · 5 shared papers, 2012–2021 · strength 0.24
  24. Stephen W. Behrman · 5 shared papers, 2012–2021 · strength 0.24
  25. Mokenge Peter Malafa · 5 shared papers, 2012–2021 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.